Logo

Blueprint Medicines' Ayvakit (avapritinib) Receives FDA's Approval to Treat Patients with Advanced Systemic Mastocytosis

Share this

Blueprint Medicines' Ayvakit (avapritinib) Receives FDA's Approval to Treat Patients with Advanced Systemic Mastocytosis

Shots:

  • The full FDA approval is based on data from 2 clinical trials i.e.- P-I EXPLORER & P-II PATHFINDER trial evaluating the efficacy of Ayvakit (200 mg- PO- qd) in 53 adults with advanced SM including ASM- SM-AHN & MCL
  • Results: @median follow-up of 11.6 mos.- ORR (57%)- CR/CRh (28%)- PR (28 %) & clinical improvement (15%)- m-DoR (38.3 mos.). Treatment response was evaluated using modified IWG-MRT-ECNM criteria & additional efficacy measures are DoR- resolution- >50% reductions in biomarker response- mast cell burden & serum tryptase
  • Ayvakit is not recommended for patients with low platelet counts (<50-000/µL). This approval marks the 1st targeted therapy that inhibits D816V mutant KIT

  | Ref: Blueprint Medicines | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions